NTRA
Natera, Inc. NASDAQ Listed Jul 1, 2015$219.69
After hrs
$196.15
+0.99%
Mkt Cap $31.1B
52w Low $131.81
70.6% of range
52w High $256.36
50d MA $202.05
200d MA $197.84
P/E (TTM)
-136.4x
EV/EBITDA
-115.4x
P/B
16.6x
Debt/Equity
0.1x
ROE
-12.2%
P/FCF
287.1x
RSI (14)
—
ATR (14)
—
Beta
1.68
50d MA
$202.05
200d MA
$197.84
Avg Volume
1.2M
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
13011 McCallen Pass Building A · Austin, CA 78753 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.53 | -0.56 | -5.7% | 219.82 | -4.5% | -11.6% | — | — | — | — | — |
| Feb 26, 2026 | AMC | -0.51 | 0.35 | +168.4% | 216.10 | -2.4% | -3.7% | -7.4% | -4.2% | -6.0% | -8.8% | — |
| Nov 6, 2025 | AMC | -0.39 | -0.64 | -65.9% | 198.48 | -6.1% | +0.5% | +4.1% | +4.2% | +5.6% | +1.1% | — |
| Aug 7, 2025 | AMC | -0.62 | -0.74 | -20.2% | 141.08 | +14.8% | +7.7% | +11.3% | +13.3% | +11.8% | +12.3% | — |
| May 8, 2025 | AMC | -0.64 | -0.50 | +21.9% | 162.57 | +1.3% | -6.5% | -3.2% | -6.3% | -6.9% | -8.1% | — |
| Feb 27, 2025 | AMC | -0.38 | -0.41 | -7.6% | 156.61 | +2.1% | -0.7% | -8.6% | -9.1% | -5.5% | -9.6% | — |
| Nov 12, 2024 | AMC | -0.57 | -0.26 | +54.4% | 135.12 | +15.1% | +19.1% | +11.8% | +8.1% | +13.5% | +20.0% | — |
| Aug 8, 2024 | AMC | -0.69 | -0.30 | +56.5% | 107.70 | -2.0% | +6.4% | +7.0% | +10.5% | +10.0% | +13.5% | — |
| May 9, 2024 | AMC | -0.71 | -0.56 | +21.1% | 95.55 | +13.1% | +10.2% | +8.1% | +10.4% | +12.3% | +13.6% | — |
| Feb 28, 2024 | AMC | -0.73 | -0.64 | +12.3% | 76.55 | +12.0% | +13.0% | +16.8% | +17.8% | +14.5% | +17.9% | — |
| Nov 8, 2023 | AMC | -0.96 | -0.95 | +1.0% | 41.34 | +14.9% | +9.8% | +13.1% | +17.4% | +26.1% | +28.1% | — |
| Aug 3, 2023 | AMC | -1.09 | -0.97 | +11.0% | 43.40 | +14.0% | +17.6% | +17.6% | +21.5% | +20.4% | +22.9% | — |
| May 9, 2023 | AMC | -1.15 | -1.23 | -7.0% | 53.00 | +2.6% | -3.4% | -2.6% | -3.6% | -1.6% | -3.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3 | Morgan Stanley | Maintains | Overweight → Overweight | — | $200.17 | $195.67 | -2.2% | +3.4% | +1.4% | -1.5% | -1.0% | +2.5% |
| Feb 27 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $216.10 | $211.02 | -2.4% | -3.7% | -7.4% | -4.2% | -6.0% | -8.8% |
| Feb 27 | Evercore ISI | Maintains | Outperform → Outperform | — | $216.10 | $211.02 | -2.4% | -3.7% | -7.4% | -4.2% | -6.0% | -8.8% |
| Feb 27 | Baird | Maintains | Outperform → Outperform | — | $216.10 | $211.02 | -2.4% | -3.7% | -7.4% | -4.2% | -6.0% | -8.8% |
| Jan 5 | Guggenheim | Maintains | Buy → Buy | — | $228.84 | $229.88 | +0.5% | +3.7% | +8.7% | +11.2% | +4.7% | +2.4% |
| Dec 22 | Canaccord Genuity | Maintains | Buy → Buy | — | $231.96 | $233.91 | +0.8% | +1.6% | +1.5% | +1.5% | +0.8% | -0.3% |
| Dec 15 | Barclays | Maintains | Overweight → Overweight | — | $231.95 | $229.29 | -1.1% | -1.5% | -2.0% | -2.8% | -3.1% | +0.0% |
| Dec 15 | JP Morgan | Maintains | Overweight → Overweight | — | $231.95 | $229.29 | -1.1% | -1.5% | -2.0% | -2.8% | -3.1% | +0.0% |
| Dec 15 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $231.95 | $229.29 | -1.1% | -1.5% | -2.0% | -2.8% | -3.1% | +0.0% |
| Dec 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $244.55 | $245.33 | +0.3% | -2.2% | -3.7% | -4.7% | -5.5% | -5.2% |
| Dec 5 | BTIG | Maintains | Buy → Buy | — | $242.06 | $242.22 | +0.1% | +1.0% | -1.2% | -2.7% | -3.7% | -4.5% |
| Dec 2 | Morgan Stanley | Maintains | Overweight → Overweight | — | $234.25 | $236.95 | +1.2% | +1.0% | +1.7% | +3.3% | +4.4% | +2.1% |
| Nov 25 | JP Morgan | Maintains | Overweight → Overweight | — | $238.58 | $240.40 | +0.8% | -0.9% | -0.6% | +0.1% | -1.8% | -0.8% |
| Nov 18 | UBS | Maintains | Buy → Buy | — | $206.04 | $204.73 | -0.6% | +3.7% | +6.0% | +9.5% | +11.9% | +15.8% |
| Nov 13 | Stephens & Co. | Maintains | Overweight → Overweight | — | $209.50 | $206.46 | -1.5% | -4.2% | -2.5% | -1.7% | +2.0% | +4.2% |
| Nov 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $206.63 | $207.44 | +0.4% | +0.0% | +1.4% | -2.9% | -1.1% | -0.3% |
| Nov 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $206.63 | $207.44 | +0.4% | +0.0% | +1.4% | -2.9% | -1.1% | -0.3% |
| Nov 7 | Barclays | Maintains | Overweight → Overweight | — | $198.48 | $186.28 | -6.1% | +0.5% | +4.1% | +4.2% | +5.6% | +1.1% |
| Nov 7 | JP Morgan | Maintains | Overweight → Overweight | — | $198.48 | $186.28 | -6.1% | +0.5% | +4.1% | +4.2% | +5.6% | +1.1% |
| Nov 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $198.48 | $186.28 | -6.1% | +0.5% | +4.1% | +4.2% | +5.6% | +1.1% |
| Nov 7 | Evercore ISI | Maintains | Outperform → Outperform | — | $198.48 | $186.28 | -6.1% | +0.5% | +4.1% | +4.2% | +5.6% | +1.1% |
| Nov 7 | BTIG | Maintains | Buy → Buy | — | $198.48 | $186.28 | -6.1% | +0.5% | +4.1% | +4.2% | +5.6% | +1.1% |
| Nov 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $198.48 | $186.28 | -6.1% | +0.5% | +4.1% | +4.2% | +5.6% | +1.1% |
| Oct 23 | BTIG | Maintains | Buy → Buy | — | $188.02 | $187.16 | -0.5% | +3.7% | +2.4% | +2.2% | +0.8% | +2.5% |
| Oct 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $174.17 | $173.00 | -0.7% | -0.8% | +3.0% | +3.7% | +4.3% | +8.3% |
| Aug 15 | Stephens & Co. | Maintains | Overweight → Overweight | — | $158.44 | $158.46 | +0.0% | +2.9% | +1.7% | +1.1% | +1.4% | +2.2% |
| Aug 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $151.95 | $151.05 | -0.6% | +3.3% | +5.2% | +3.8% | +4.3% | +7.3% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $141.08 | $162.00 | +14.8% | +7.7% | +11.3% | +13.3% | +11.8% | +12.3% |
| Aug 8 | Barclays | Maintains | Overweight → Overweight | — | $141.08 | $162.00 | +14.8% | +7.7% | +11.3% | +13.3% | +11.8% | +12.3% |
| May 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $151.34 | $151.34 | +0.0% | -1.3% | +0.8% | +1.3% | +2.1% | -0.2% |
| May 9 | UBS | Maintains | Buy → Buy | — | $162.57 | $164.75 | +1.3% | -6.5% | -3.2% | -6.3% | -6.9% | -8.1% |
| May 9 | Barclays | Maintains | Overweight → Overweight | — | $162.57 | $164.75 | +1.3% | -6.5% | -3.2% | -6.3% | -6.9% | -8.1% |
| Apr 10 | Barclays | Maintains | Overweight → Overweight | — | $151.97 | $146.24 | -3.8% | -5.7% | -2.6% | -2.3% | -0.2% | -1.2% |
| Mar 5 | Morgan Stanley | Maintains | Overweight → Overweight | — | $142.35 | $142.09 | -0.2% | +3.9% | -0.6% | -1.2% | -6.8% | -1.6% |
| Mar 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $143.11 | $140.37 | -1.9% | -0.5% | +3.4% | -1.1% | -1.7% | -7.3% |
| Feb 28 | Canaccord Genuity | Maintains | Buy → Buy | — | $156.61 | $159.94 | +2.1% | -0.7% | -8.6% | -9.1% | -5.5% | -9.6% |
| Feb 28 | Baird | Maintains | Outperform → Outperform | — | $156.61 | $159.94 | +2.1% | -0.7% | -8.6% | -9.1% | -5.5% | -9.6% |
| Feb 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $156.00 | $155.31 | -0.4% | +2.9% | +0.4% | -0.3% | -8.3% | -8.8% |
| Jan 28 | Goldman Sachs | Maintains | Buy → Buy | — | $165.26 | $165.49 | +0.1% | +1.7% | +1.8% | +6.7% | +7.1% | +6.8% |
| Jan 17 | Guggenheim | Maintains | Buy → Buy | — | $168.50 | $168.92 | +0.2% | -6.0% | -0.6% | +2.0% | +2.0% | -0.5% |
| Jan 10 | Bernstein | Maintains | Outperform → Outperform | — | $176.61 | $173.02 | -2.0% | -0.9% | -4.1% | -6.1% | -3.5% | -4.6% |
| Jan 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $160.60 | $162.65 | +1.3% | +4.4% | +7.3% | +6.1% | +10.0% | +9.0% |
| Dec 13 | JP Morgan | Maintains | Overweight → Overweight | — | $166.45 | $168.20 | +1.1% | +0.1% | +2.6% | +1.1% | -6.8% | -5.0% |
| Nov 18 | Piper Sandler | Maintains | Overweight → Overweight | — | $146.06 | $150.60 | +3.1% | +5.0% | +11.0% | +14.9% | +16.0% | +14.5% |
| Nov 14 | Morgan Stanley | Maintains | Overweight → Overweight | — | $160.97 | $160.79 | -0.1% | -6.1% | -9.3% | -4.7% | +0.7% | +4.3% |
| Nov 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $135.12 | $155.56 | +15.1% | +19.1% | +11.8% | +8.1% | +13.5% | +20.0% |
| Nov 13 | TD Cowen | Maintains | Buy → Buy | — | $135.12 | $155.56 | +15.1% | +19.1% | +11.8% | +8.1% | +13.5% | +20.0% |
| Nov 13 | Baird | Maintains | Outperform → Outperform | — | $135.12 | $155.56 | +15.1% | +19.1% | +11.8% | +8.1% | +13.5% | +20.0% |
| Nov 13 | JP Morgan | Maintains | Overweight → Overweight | — | $135.12 | $155.56 | +15.1% | +19.1% | +11.8% | +8.1% | +13.5% | +20.0% |
| Nov 13 | Craig-Hallum | Maintains | Buy → Buy | — | $135.12 | $155.56 | +15.1% | +19.1% | +11.8% | +8.1% | +13.5% | +20.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 948 | $205.22 | $195K | 2,377,843 | +2.20% | — |
| May 5, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 1,697 | $206.77 | $351K | 2,376,402 | +2.20% | — |
| May 5, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 1,454 | $241.39 | $351K | 2,378,099 | +2.20% | — |
| May 5, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 2,887 | $206.77 | $597K | 2,379,553 | +2.20% | — |
| May 4, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 722 | $206.16 | $149K | 2,382,440 | +2.20% | — |
| May 4, 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 482 | $210.49 | $101K | 57,496 | +4.02% | — |
| May 1, 2026 | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | Sell | 150 | $206.93 | $31K | 142,295 | +4.02% | — |
| May 1, 2026 | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | Sell | 400 | $205.31 | $82K | 142,445 | +4.02% | — |
| May 1, 2026 | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | Sell | 865 | $204.47 | $177K | 142,845 | +4.02% | — |
| May 1, 2026 | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | Sell | 505 | $203.32 | $103K | 143,710 | +4.02% | — |
| May 1, 2026 | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | Sell | 520 | $201.60 | $105K | 144,215 | +4.02% | — |
| May 1, 2026 | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | Sell | 560 | $200.95 | $113K | 144,735 | +4.02% | — |
| May 1, 2026 | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | Sell | 405 | $206.16 | $83K | 145,295 | +4.02% | — |
| May 1, 2026 | RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sell | 330 | $206.16 | $68K | 222,694 | +4.02% | — |
| May 1, 2026 | Sheena Jonathan | — | Sell | 107 | $206.16 | $22K | 255,652 | +4.02% | — |
| May 1, 2026 | Fesko John | PRESIDENT, CHIEF BUS. OFFICER | Sell | 291 | $206.16 | $60K | 187,220 | +4.02% | — |
| May 1, 2026 | Chapman Steven Leonard | CEO AND PRESIDENT | Sell | 902 | $206.16 | $186K | 149,867 | +4.02% | — |
| May 1, 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 313 | $206.16 | $65K | 57,978 | +4.02% | — |
| Apr 29, 2026 | Sheena Jonathan | — | Sell | 805 | $196.99 | $159K | 255,711 | +5.86% | +10.44% |
| Apr 29, 2026 | Sheena Jonathan | — | Sell | 2,266 | $196.22 | $445K | 256,516 | +5.86% | +10.44% |
| Apr 29, 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 200 | $197.26 | $39K | 58,291 | +5.86% | +10.44% |
| Apr 29, 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 1,070 | $194.82 | $208K | 58,491 | +5.86% | +10.44% |
| Apr 29, 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 1,000 | $193.78 | $194K | 59,561 | +5.86% | +10.44% |
| Apr 29, 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 500 | $192.13 | $96K | 60,561 | +5.86% | +10.44% |
| Apr 29, 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 300 | $190.12 | $57K | 61,061 | +5.86% | +10.44% |
| Apr 27, 2026 | Sheena Jonathan | — | Sell | 188 | $204.39 | $38K | 258,782 | +5.86% | +10.44% |
| Apr 27, 2026 | Sheena Jonathan | — | Sell | 285 | $203.75 | $58K | 258,970 | +5.86% | +10.44% |
| Apr 27, 2026 | RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sell | 988 | $204.39 | $202K | 223,024 | +5.86% | +10.44% |
| Apr 27, 2026 | RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sell | 873 | $203.75 | $178K | 224,012 | +5.86% | +10.44% |
| Apr 27, 2026 | Fesko John | PRESIDENT, CHIEF BUS. OFFICER | Sell | 917 | $204.39 | $187K | 187,511 | +5.86% | +10.44% |
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Natera's executive compensation structure includes multi-year equity vesting incentives through 2029, indicating management retention strategy but diluting shareholder value over time through substantial stock awards.
Apr 1
8-K
Natera, Inc. -- 8-K Filing
Natera reported fourth quarter and full year 2025 financial results, with CFO Michael Brophy executing the filing on February 26, 2026.
Feb 26
Data updated apr 26, 2026 4:01pm
· Source: massive.com